Amgen(US:AMGN) Ge Long Hui A P P·2026-01-06 14:28Core Viewpoint - Amgen has acquired cancer drug developer Dark Blue for a total of $840 million, aiming to further expand its oncology product line [1] Group 1: Acquisition Details - The acquisition amount is $840 million [1] - Dark Blue is a private company based in the UK, focusing on the development of a drug known as "protein degraders" [1] - The acquisition is part of Amgen's strategy to strengthen its research in targeted protein degradation and leukemia treatment [1] Group 2: Product Development - Dark Blue's most advanced compound has not yet entered clinical trials but is expected to provide a new therapy for acute myeloid leukemia [1] - The field of protein degraders has become a hot target for major pharmaceutical companies like Novartis and Gilead Sciences [1] Group 3: Strategic Implications - Amgen's Executive Vice President of R&D, Jay Bradner, stated that the acquisition enhances and expands their research in targeted protein degradation and leukemia treatment [1] - The move aligns with Amgen's strategy of early investment in emerging targets [1]